Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2013-01-22

Clinical Trial Update: Chemotherapy Followed by gp100 Lymphocytes and Aldesleukin to Treat Melanoma [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating chemotherapy followed by gp100 lymphocytes and aldesleukin for metastatic melanoma; the study completed and results were posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Aldesleukin (interleukin-2)
  • gp100 lymphocytes (gp100-specific cytotoxic T lymphocytes)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Skin Cancer, Metastatic Melanoma | Phase 2 | Status: COMPLETED | Results posted: 2013-01-22